Brukinsa shows a more favorable safety profile than Imbruvica, with fewer severe side effects, especially neutropenia. Brukinsa may be preferable for patients at higher infection risk or requiring ...
Brukinsa showed a 32% reduction in disease progression or death risk compared to Imbruvica, with a 49% reduction in del(17p)/TP53 mutation patients. Higher overall response rate was observed with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback